Related Experiment Video
Updated: Jan 9, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Cardiac characteristics of Fabry disease from baseline enrolment data in a nationwide prospective Japanese registry
Toru Kubo1, Yuichiro Maekawa2, Kenichi Hongo3
1Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan.
Insights
This study presents baseline data from 175 Japanese Fabry disease (FD) patients, highlighting cardiac involvement and device implantation. Findings offer insights into managing cardiovascular complications in FD.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Rare Diseases
Background:
- Fabry disease (FD) is a significant cardiovascular concern, with cardiac lesions being a primary cause of mortality.
- Understanding the baseline characteristics of FD patients is crucial for effective management and treatment strategies.
Purpose of the Study:
- To establish the first large-scale prospective registry of Fabry disease patients in Japan.
- To collect and present baseline clinical characteristics, focusing on cardiac features and management.
Main Methods:
- A multicenter prospective registration study was conducted across Japan.
- Data from 175 Fabry disease patients were analyzed for baseline clinical characteristics.
Main Results:
- The average age at enrollment was 52 years, with 38% males. Left ventricular hypertrophy (LVH) was prevalent, with 77% showing concentric diffuse patterns.
- Electrocardiography revealed short PQ intervals in 12% and short PendQ intervals in 33% of patients with LVH.
- Cardiac device implantation included pacemakers in 5% and defibrillators in 7% of patients.
Conclusions:
- This study provides valuable baseline data on the cardiac manifestations and management of Fabry disease in Japan.
- The findings serve as a foundation for future research and clinical guidelines for FD patients.
Background:
Fabry disease (FD) is an important disease in the cardiovascular field because a significant proportion of patients with FD die from cardiac lesions.
Methods:
A multicenter prospective registration study of patients with FD throughout Japan was designed. The baseline clinical characteristics of 175 patients are presented here.
Results:
The mean ages at enrolment and at diagnosis were 52 ± 16 and 43 ± 18 years, respectively, with men accounting for 38 % of the patients. In the cohort, 24 % of the patients had the classical hemizygote male type, whereas 14 % had the late-onset male type, and 62 % had the heterozygote female type. On electrocardiography data at enrolment in 92 patients with left ventricular hypertrophy (LVH) (maximum LV wall thickness > 12 mm), 12 % showed a short PQ interval (< 120 msec), and 33 % had a short PendQ interval (≤ 40 msec). The Sokolow-Lyon voltage was high (6.1 ± 13.1 mv). Regarding the distribution of LVH patterns, 77 % of the patients showed concentric diffuse LVH, 16 % of the patients had asymmetric septal hypertrophy, and 1 % of the patients had hypertrophy confined to the LV apex. With regard to implantation of cardiac devices, permanent pacemakers had been implanted in 5 % of the patients and defibrillators had been implanted in 12 patients (7 %), for primary prevention in nine patients and for secondary prevention in three patients.
Conclusion:
As the first large-scale prospective registry of FD patients in Japan, this study has provided valuable baseline data for the cardiac features and management of FD.
More Related Videos
Related Concept Videos
Coronary Artery Disease III: Clinical Manifestations
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy I: Introduction and Classification
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease I: Introduction

